Editas Medicine (NASDAQ:EDIT) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Editas Medicine (NASDAQ:EDIT) from a sell rating to a hold rating in a research note released on Saturday.

Several other equities research analysts have also recently issued reports on EDIT. TD Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a report on Wednesday, May 27th. Chardan Capital increased their price target on Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Editas Medicine in a report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.40.

Editas Medicine Stock Performance

EDIT stock opened at $2.88 on Friday. Editas Medicine has a one year low of $1.66 and a one year high of $4.54. The company’s fifty day moving average price is $2.90 and its 200-day moving average price is $2.64. The company has a market capitalization of $281.98 million, a PE ratio of -3.84 and a beta of 2.14.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%. On average, research analysts predict that Editas Medicine will post -0.93 EPS for the current fiscal year.

Insider Activity at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total value of $41,526.00. Following the sale, the chief executive officer directly owned 248,313 shares in the company, valued at $670,445.10. The trade was a 5.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 21,503 shares of company stock valued at $57,910. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in EDIT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Editas Medicine by 122.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock worth $3,016,000 after acquiring an additional 1,430,000 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Editas Medicine by 288.5% in the 1st quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock valued at $869,000 after purchasing an additional 558,567 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Editas Medicine by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,964,298 shares of the company’s stock valued at $4,323,000 after purchasing an additional 20,521 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Editas Medicine by 15.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,065,722 shares of the company’s stock worth $2,345,000 after purchasing an additional 140,916 shares during the period. Finally, Bridgeway Capital Management LLC increased its position in shares of Editas Medicine by 500.0% during the 2nd quarter. Bridgeway Capital Management LLC now owns 120,000 shares of the company’s stock valued at $264,000 after purchasing an additional 100,000 shares during the last quarter. Hedge funds and other institutional investors own 71.90% of the company’s stock.

Key Headlines Impacting Editas Medicine

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: HC Wainwright sharply reduced projected losses. The firm raised its FY2026 EPS forecast to a loss of $0.66 from $1.04 and its FY2027 forecast to a loss of $0.70 from $1.15. It also narrowed expected losses for multiple 2026–2027 quarters, including Q3 2026 to $0.20 per share from $0.33 and Q4 2026 to $0.08 from $0.13. The revisions suggest better-than-previously expected operating performance, although Editas is still projected to remain unprofitable.
• Positive Sentiment: Recent quarterly results provided additional support. Editas reported a quarterly loss of $0.15 per share, better than the $0.27 consensus estimate, while revenue of $11.89 million exceeded the $2.85 million forecast. However, the company continues to post substantial net losses.
• Neutral Sentiment: Wall Street Zen upgraded Editas Medicine to “Hold.” The change indicates a less-negative stance but does not represent a bullish recommendation, limiting its potential to drive sustained buying. Editas Medicine upgraded to Hold at Wall Street Zen
• Negative Sentiment: Editas remains a loss-making biotechnology company. Analysts still expect a full-year loss of approximately $1.03 per share, and the company reported a negative net margin. With no new clinical or commercial catalyst in these reports, investors may have viewed the estimate revisions as insufficient to offset ongoing profitability and funding risks.

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.